Welcome to our dedicated page for Marchex SEC filings (Ticker: MCHX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Marchex, Inc. filings document the regulatory record for a Delaware operating company that provides AI-based conversational intelligence and analytics solutions. Its disclosures cover operating and financial results, material agreements, capital-structure matters, governance actions, legal proceedings, and risk factors tied to its conversational analytics business.
Recent filings include Form 8-K material-event reports, proxy materials for annual meeting matters, and compensation disclosures involving cash awards, restricted stock units, stock options, and the 2021 Stock Incentive Plan. The filings also describe the company's Class A and Class B common stock voting structure, board and stockholder voting matters, lease-related agreements and impairments, and settlement documentation for civil litigation.
Marchex (MCHX) reported an insider equity grant to its Chief Operating Officer & CLO. On 10/16/2025, the executive received 150,000 restricted stock units, each settling into one share of Class B Common Stock, vesting in full on the fourth anniversary of the grant date.
On the same date, the executive was also granted 150,000 stock options with a $1.81 exercise price, expiring on 10/16/2035. The options vest over four years: 25% on the first anniversary, then quarterly in equal 6.25% increments over the next three years.
Marchex (MCHX) filed a Form 4 reporting equity awards to its President & Chief Revenue Officer effective October 16, 2025. The filing discloses 150,000 restricted stock units, each convertible into one share of Class B Common Stock, vesting in full on the fourth anniversary of the grant date. It also reports stock options for 150,000 shares at an exercise price of $1.81 per share, expiring October 16, 2035, vesting 25% on the first anniversary and the remainder in equal quarterly installments over the next three years.
Francis J. Feeney, Chief Operating Officer of Marchex, Inc. (MCHX), filed a Form 3 disclosing his initial beneficial ownership. The filing reports 277,428 shares of Class B common stock held directly and a portfolio of equity awards that could convert to additional shares.
The derivative holdings include employee stock options to purchase 848,000 shares with exercise prices ranging from $1.45 to $5.05 and expiration dates between 2028 and 2034, plus 62,500 restricted stock units that vest in full on the first anniversary of their March 20, 2025 grant. All reported holdings are direct and subject to specified vesting schedules tied to continued employment.
Marchex, Inc. reported a major leadership transition. Edwin A. Miller resigned as Chief Executive Officer effective September 11, 2025, and will serve for one year as a consultant to the company’s Chairman, providing general advisory services for $150,000 in annual compensation and remaining eligible for his 2025 annual cash performance bonus.
Effective September 15, 2025, Troy Hartless was appointed President while continuing as Chief Revenue Officer, and Francis J. Feeney was appointed Chief Operating Officer while continuing as Chief Legal Officer. Brian Nagle was appointed Chief Financial Officer, moving up from Senior Vice President, Controller. Hartless and Feeney will serve as Co-Principal Executive Officers for SEC reporting purposes. The company states there were no changes in compensation for Hartless, Feeney, or Nagle in connection with these appointments and discloses no related-party transactions or family relationships.
Marchex reported revenue of $11.655 million for the quarter ended June 30, 2025, down 3% from $12.074 million a year earlier, and $23.058 million for the six months, down 2% year over year. The company recorded a small quarterly net income of $85 thousand (basic and diluted EPS $0.00) after narrowing its operating loss, but posted a six-month net loss of $1.897 million (basic/diluted loss per share approximately $0.04). Cash and cash equivalents were $10.491 million, total assets $41.984 million, and accumulated deficit $328.075 million.
Operational highlights: sales and marketing expense increased while product development declined due to capitalization and reorganization; cost of revenue remained ~35% of revenue. The company recognized a ~$0.6 million gain from a domain sale, authorized a new repurchase program to buy up to 3,000,000 Class B shares (no repurchases made), and recorded a 100% valuation allowance against deferred tax assets. One customer accounted for ~11% of revenue and 21% of receivables, and litigation over a prior acquisition earnout is in discovery.
Marchex, Inc. announced it is issuing an earnings release and holding a conference call to report results for the quarter ended June 30, 2025. The full earnings release is furnished as Exhibit 99.1 to the Current Report. The company discloses it will present both GAAP and non-GAAP financial measures; the release includes reconciliations and definitions explaining why management believes the non-GAAP measures are useful to investors. The 8-K furnishes this information rather than treating it as formally "filed" under the Exchange Act.